Navigation Links
Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program.
Date:5/25/2010

ALLENTOWN, Pa. and CAMPBELL, Calif., May 25 /PRNewswire/ -- HunterHeart offers physicians and patients sophisticated risk characterization and personalized therapy guidelines for cardiovascular disease.  HNL will be performing a battery of advanced tests, offering an accompanying nutrition program, and wellness coaching.  Gerry Weiss, MD, Hunter's Medical Director stated:  "With appropriate risk characterization and treatment, cardiovascular disease can be prevented for many patients and MI and stroke events can be significantly reduced."

"HNL's reputation for quality, service and innovation is exceptional.  Hunter is delighted to be working with HNL to reduce cardiovascular disease in PA and NJ," stated Chris Riedel, Hunter's CEO.  HNL's President and CEO, David G. Beckwith Ph.D., stated that, "The HunterHeart program will assist our physicians in delivering comprehensive cardiovascular health advice to their patients, and establishes HNL as a center of excellence for preventive cardiology."

About Health Network Laboratories

Based in Allentown, Pennsylvania, Health Network Laboratories (HNL) is a multi-regional medical laboratory with technologically advanced facilities in Pennsylvania and New Jersey.  HNL serves the need of the public and health care communities performing almost 6 million clinical and pathology tests each year.  HNL is consistently rated highly by physicians and clients in all areas of laboratory performance and customer satisfaction.

HNL offers a full complement of clinical laboratory and anatomic pathology services, including highly specialized esoteric testing to hospitals, physicians, long-term and assisted living facilities, businesses and government agencies.  For more information, visit http://www.healthnetworklabs.com/

About Hunter Labs, Inc.

Hunter Laboratories is the largest locally owned and operated clinical reference laboratory in northern California.  HunterHeart is one of Hunter's proprietary disease detection and management programs that are being rolled-out across the U.S.  Hunter's Incelldx mRNA test for cervical cancer detection is also being introduced across the U.S.  This test is the only accurate HPV method for women under 30, and has better specificity for predicting CIN2/CIN3 on biopsy.  For more information, visit http://www.hunterlabs.com/.


'/>"/>
SOURCE Hunter Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phreesia to Accelerate Growth with $16 Million Investment Led by Ascension Health Ventures
2. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
3. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
4. AstraZeneca Donates $1 Million for Christiana Care Health Systems Wilmington Hospital Project
5. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
6. Home Health Monitoring May Significantly Improve Blood Pressure Control, Kaiser Permanente Study Finds
7. Accuray Incorporated to Present at Citi Global Health Care Conference
8. Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference
9. Inverness Medical Innovations to Attend the Citi Global Health Care Conference on May 26, 2010
10. Medco to Present at the 2010 Citi Investment Research Global Health Care Conference
11. WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):